Accuronix Therapeutics Inc is a cutting-edge biotechnology company based in St. Louis, MO, dedicated to developing innovative cancer therapies. Utilizing a unique drug-targeting technology, the company focuses on addressing the most challenging issues in cancer treatment, with an initial emphasis on pancreatic cancer.
With strategic partnerships with renowned institutions like Washington University and the University of Pennsylvania, Accuronix Therapeutics aims to develop groundbreaking oncology therapies that selectively target -2 receptors, which are known to be overexpressed on cancer cells. Led by President and CEO Bradley T. Keller, Ph.D., the company is committed to pushing the boundaries of cancer therapy and making a significant impact in the field of oncology.
Generated from the website